Erlotinib, in combination with bevacizumab for the maintenance treatment of non-squamous advanced or metastatic non-small-cell lung cancer after previous platinum-containing chemotherapy
| Status: |
Suspended |
| Expected date of issue: |
TBC |
| Referral date: |
November 2008 |
| Wave: |
19 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
TBC
|
| Technical Lead: |
TBC
|
| Communications manager: |
TBC
|
| Project manager: |
TBC
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
Consultees and commentators
Project history
| Date |
Update |
| 30 July 2010 |
The manufacturer of erlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to suspend this appraisal from its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (cathryn.hall@nice.org.uk).
|
| 13 August |
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early August 2010. The deadline for submissions is expected in approximately early October 2010. |
|
Key documents
This page was last updated: 12 August 2010
